RESOMER LG 855 S Bioresorbable PLGA Medical Grade is a poly(L-lactide-co-glycolide) copolymer with a nominal comonomer ratio of 85:15 L-lactide to glycolide. The grade is supplied as a solid resin for formulation into sustained-release parenteral drug delivery systems, absorbable implant matrices, coatings, and porous scaffolds. Manufacturer documentation typically characterizes the polymer by inherent viscosity measured at 0.1% w/v in chloroform at 25 °C; lot-specific values for related 85:15 PLGA grades commonly fall between 0.50 dL/g and 0.75 dL/g, corresponding to a weight-average molecular weight range of approximately 70,000 g/mol to 120,000 g/mol when determined by gel permeation chromatography against polystyrene standards. The designation “S” is supplier-specific and should be confirmed against the certificate of analysis for end-group chemistry and molecular weight distribution. This resin is intended for use under recognized biocompatibility evaluation frameworks such as ISO 10993-1:2018; certification of the polymer alone does not establish safety of a finished medical device.

What Limits the Processing Window in Solvent-Based Microsphere Fabrication?

The dominant process constraint for RESOMER LG 855 S in solvent-based microsphere preparation is the viscosity of the polymer continuous phase and the rate of solvent extraction from the dispersed phase. In double-emulsion solvent evaporation, the polymer is dissolved in dichloromethane or ethyl acetate at concentrations from 5% w/v to 20% w/v. Higher solution viscosity retards droplet break-up in a rotor-stator homogenizer operating at 5,000 rpm to 15,000 rpm, shifting the volume mean diameter upward and broadening the span unless the dispersed phase is pre-filtered through a 0.22 µm hydrophobic membrane. The high lactide content of the 85:15 grade delays bulk hydrolysis compared with 50:50 PLGA, making it suitable for release intervals beyond 4 weeks. In vitro release studies for similar 85:15 PLGA microspheres have been conducted in phosphate-buffered saline at pH 7.4 and 37 °C under sink conditions; published degradation half-lives for 85:15 copolymers are typically 3 to 5 months, depending on molecular weight, end-group chemistry, and implant geometry. Residual dichloromethane must be controlled below the concentration limit set in ICH Q3C for parenteral products, with vacuum drying at 40 °C and 0.1 bar until the headspace gas chromatography result is < 600 ppm.

Differences between RESOMER LG 855 S and lower-lactide or higher-lactide grades become most evident under hydrated conditions. A 50:50 PLGA of similar molecular weight degrades more rapidly, often losing more than 50% of its mass in 6 to 8 weeks in vitro, whereas 85:15 retains structural mass for 4 to 6 months in comparable form factors. A 75:25 intermediate grade exhibits an intermediate hydrolysis profile. The higher L-lactide content also reduces solubility in polar solvents such as acetonitrile, methyl ethyl ketone, and methanol-water mixtures. For drug-polymer compatibility screening, solutions in dichloromethane are preferred; the polymer shows limited solubility in pure water, ethanol, and hexane. These differences require that formulation scientists not substitute another 85:15 PLGA or a 50:50 grade without re-validating release profiles, mechanical integrity, and residual solvent clearance.

Thermal, Rheological, and Residual Solvent Specifications

Dry-state thermal analysis of 85:15 PLGA places the glass transition temperature between 50 °C and 55 °C by differential scanning calorimetry at a heating rate of 10 °C/min according to ASTM D3418-21. The copolymer is predominantly amorphous after rapid cooling from the melt, although slow cooling or annealing above the glass transition can induce limited crystallization of L-lactide sequences. Melt processing is feasible when a stable melt is required, but the working window is bounded by thermal degradation at temperatures above 200 °C and by insufficient plasticization near the glass transition. Injection molding of the polymer is typically evaluated with a barrel profile from 160 °C to 185 °C and a mold temperature from 20 °C to 30 °C. The inherent viscosity should be rechecked before melt processing if the resin has been stored outside sealed foil pouches at a relative humidity above 60%, because hydrolytic chain scission occurs within hours at elevated humidity. Pre-drying under vacuum at 40 °C for 12 h reduces residual moisture to below 500 ppm as measured by Karl Fischer titration.

Comparative release and mechanical performance are governed less by the nominal 85:15 ratio than by end-group chemistry, molecular weight, residual monomer content, and tin residue. The acid-terminated H grades of PLGA typically hydrate faster and exhibit a more pronounced autocatalytic degradation rate than non-acid-initiated polymer of the same comonomer ratio. Suppliers frequently provide residual monomer specifications for glycolide at < 0.5% and lactide at < 0.5%, with tin catalyst residues below 150 ppm for pharmacopoeially aligned monographs. This is a critical distinction because residual monomer accelerates the initial burst release from microparticles and can lower the glass transition temperature by plasticization. The exact end-group molar proportion for RESOMER LG 855 S should be confirmed by ¹H NMR from the certificate of analysis.

If a Higher-Viscosity, Slower-Degrading Implant Matrix Is Required

An increase in inherent viscosity from 0.50 dL/g to 0.75 dL/g raises the dry tensile strength of 85:15 PLGA films from approximately 30 MPa to 45 MPa when tested under ISO 527-2:2012 at 23 °C and 50% RH. This shift also reduces the rate of water uptake and extends the lag phase before mass loss begins. However, higher molecular weight increases the pressure drop across sterile filters and can reduce the encapsulation efficiency of heat-labile peptides if the solvent evaporation rate is held constant. Published data for this specific grade at implant-relevant thickness is limited; end users should perform design verification on finished device geometry rather than extrapolating from tensile coupons. The material’s semicrystalline potential also affects dimensional stability during gamma or electron-beam sterilization. Ionizing radiation at doses of 25 kGy or greater can reduce molecular weight through chain scission, shifting the subsequent degradation curve toward faster release; ethylene oxide processing is generally preferred for low-temperature-sensitive formulations, but residual ethylene oxide and ethylene chlorohydrin must meet ISO 10993-7:2008 limits.

RESOMER LG 855 S is not a single-specification commodity polymer. The supplier’s certificate of analysis should contain the exact monomer ratio by ¹H NMR, inherent viscosity, residual monomer by GC-FID, tin residue by ICP-MS, and loss on drying. Contract laboratories performing dissolution testing according to USP <711> may use the polymer for controlled-release parenteral formulations, but the finished product must meet its own pharmacopoeial monograph for sterility, endotoxin, and particulate matter. Because the polymer is bioresorbable, degraded oligomers enter the citric acid cycle as glycolic acid and lactic acid; this pathway is well documented but does not eliminate the need for local tissue response evaluation under ISO 10993-6:2016. The resin should be stored in sealed, desiccant-lined pouches at −20 °C to 5 °C and allowed to reach room temperature before opening to minimize moisture condensation and premature hydrolytic chain scission.